Physician profile
Kyle N Smart
NPI 1821030057
$3,360.35
in general payments reported to CMS, 2019-2025
30 companies · $642 in 2025
The $642 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.74 · 2020: $70.17 · 2021: $210 · 2022: $527 · 2023: $806 · 2024: $1,022 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,450 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,450.13 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $566.97 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $429.74 | 2022-2025 | |
| Pfizer INC. | $399.87 | 2021-2025 | |
| Merz North America, INC. | $257.42 | 2019-2023 | |
| Novo Nordisk INC | $247.94 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $216.11 | 2019-2025 | Shingrix, Bexsero, Arexvy |
| Abbvie INC. | $153.53 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.82 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $107.47 | 2022-2025 | Mounjaro, Kisunla |
| Intuitive Surgical, INC. | $97.27 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $94.37 | 2020-2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $71.55 | 2021-2023 | Steglatro, Belsomra |
| Sanofi Pasteur INC. | $67.04 | 2022-2023 | |
| Exact Sciences Corporation | $65.09 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $55.79 | 2022-2023 | Eliquis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $50.39 | 2024-2025 | Repatha, Otezla |
| Seqirus USA INC | $37.28 | 2022-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Janssen Pharmaceuticals, INC | $35.98 | 2019-2020 | |
| Edwards Lifesciences Corporation | $31.02 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Gilead Sciences, INC. | $30.56 | 2025 | |
| Astellas Pharma US INC | $25.84 | 2024 | Veozah |
| Dexcom, INC. | $25.14 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.69 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.33 | 2023 | Gvoke Hypopen |
| Allergan, INC. | $21.99 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.55 | 2024 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $20.94 | 2021 | |
| Antares Pharma, INC. | $19.27 | 2024 | Xyosted |
| Phadia US INC. | $18.01 | 2023 | Immunocap |
| Cequr Corporation | $12.38 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Smart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.